CN100420454C - Pharmaceutical composition for treating apoplexy and preparation method thereof - Google Patents
Pharmaceutical composition for treating apoplexy and preparation method thereof Download PDFInfo
- Publication number
- CN100420454C CN100420454C CNB2006100830296A CN200610083029A CN100420454C CN 100420454 C CN100420454 C CN 100420454C CN B2006100830296 A CNB2006100830296 A CN B2006100830296A CN 200610083029 A CN200610083029 A CN 200610083029A CN 100420454 C CN100420454 C CN 100420454C
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- preparation
- apoplexy
- extractum
- combination method
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000006011 Stroke Diseases 0.000 title claims abstract description 47
- 206010008190 Cerebrovascular accident Diseases 0.000 title claims abstract description 46
- 238000002360 preparation method Methods 0.000 title claims abstract description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 42
- 239000000203 mixture Substances 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims description 62
- 239000007788 liquid Substances 0.000 claims description 37
- 229940079593 drug Drugs 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000011282 treatment Methods 0.000 claims description 20
- 239000003937 drug carrier Substances 0.000 claims description 16
- 241000628997 Flos Species 0.000 claims description 12
- 239000000890 drug combination Substances 0.000 claims description 12
- 241000283690 Bos taurus Species 0.000 claims description 11
- 239000004922 lacquer Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical group O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 2
- 230000001476 alcoholic effect Effects 0.000 claims description 2
- 239000008280 blood Substances 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 208000002193 Pain Diseases 0.000 abstract description 5
- 230000017531 blood circulation Effects 0.000 abstract description 5
- 230000036407 pain Effects 0.000 abstract description 5
- 230000003213 activating effect Effects 0.000 abstract description 4
- 230000001815 facial effect Effects 0.000 abstract description 3
- 238000007796 conventional method Methods 0.000 abstract description 2
- 239000000969 carrier Substances 0.000 abstract 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 241000241550 Cyathula Species 0.000 abstract 1
- 240000003801 Sigesbeckia orientalis Species 0.000 abstract 1
- 235000003407 Sigesbeckia orientalis Nutrition 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 7
- 239000006187 pill Substances 0.000 description 7
- 239000010273 nao xue shuan Substances 0.000 description 6
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 206010004542 Bezoar Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000208340 Araliaceae Species 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- 206010019468 Hemiplegia Diseases 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000002537 thrombolytic effect Effects 0.000 description 3
- 208000006820 Arthralgia Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 2
- 244000192528 Chrysanthemum parthenium Species 0.000 description 2
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 2
- 241000903946 Clematidis Species 0.000 description 2
- 206010013952 Dysphonia Diseases 0.000 description 2
- 241000237903 Hirudo Species 0.000 description 2
- 239000009636 Huang Qi Substances 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037714 Quadriplegia Diseases 0.000 description 2
- 241000131808 Scolopendra Species 0.000 description 2
- 241001077909 Sigesbeckia Species 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 235000008384 feverfew Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000002008 hemorrhagic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- 241000427159 Achyranthes Species 0.000 description 1
- 241000271039 Agkistrodon Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 241000717739 Boswellia sacra Species 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- -1 Calculus Bovis Awake Substances 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- 241000208809 Carthamus Species 0.000 description 1
- 241000219321 Caryophyllaceae Species 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004863 Frankincense Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000015511 Liquidambar orientalis Nutrition 0.000 description 1
- 241000243684 Lumbricus Species 0.000 description 1
- 241001057584 Myrrha Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 241000764065 Persicaria capitata Species 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 241000583586 Sagina Species 0.000 description 1
- 241000239226 Scorpiones Species 0.000 description 1
- 241000117268 Sigesbeckia glabrescens Species 0.000 description 1
- 241000123886 Sigesbeckia pubescens Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004870 Styrax Substances 0.000 description 1
- 244000028419 Styrax benzoin Species 0.000 description 1
- 235000000126 Styrax benzoin Nutrition 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002605 anti-dotal effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 108010052008 colla corii asini Proteins 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002389 essential drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000009519 fu-yuan Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000009112 niuhuang Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000010356 tongguan Substances 0.000 description 1
- 239000008727 tongluo Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000009692 xuesetong Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a medical composition for treating apoplexy and/or sequelae of apoplexy, a preparation method of the composition and the application thereof. The medical composition contains active constituents of the following weight portions: 200 to 1000 portions of siegesbeckia orientalis, 10 to 100 portions of safflower and 10 to 100 portions of cyathula roots, and selectively contains one or more medicinal carriers. The medical composition has the efficacy of expelling wind, activating blood flow and activating meridians to stop pain. The medical composition is used for treating apoplexy caused by obstruction of collaterals by blood stasis and various sequelae of apoplexy, such as hemiparalysis, numb limbs, unsmooth speech, facial hemiparalysis, etc. The medical composition can be prepared into various conventional preparations, preferably oral liquors. The medical composition and various preparations containing the medical composition can be prepared according to a conventional method by applying usual carriers in the field of medical preparation.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition, concrete, the present invention relates to a kind of pharmaceutical composition that is used for the treatment of apoplexy, and the preparation method of said composition and application, said composition Han You Herba Siegesbeckiae, Flos Carthami and river cattle lacquer, and can contain one or more pharmaceutical carriers.
Background technology
Apoplexy, promptly acute cerebrovascular disease is a kind of commonly encountered diseases of grievous injury human health, is the adult, particularly old people's frequently-occurring disease and commonly encountered diseases are one of three human big dead diseases.Result according to China's Epidemiological study.The number of China's patients with cerebral apoplexy reaches 400-500 ten thousand people, and the number of annual neopathy reaches 1,300,000, because its sickness rate, mortality rate cause, residual rate and relapse rate are all higher, and therefore very harmful to human health.
By the reason and the character of morbidity, apoplexy is divided into hemorrhagic apoplexy and cerebral infarction two classes.The former comprises cerebral hemorrhage and subarachnoid hemorrhage; The latter comprises transient ischemic attack, cerebral thrombosis and cerebral infarction.Hemorrhagic apoplexy, doctor trained in Western medicine adopt operation and Drug therapy more, and curative effect is better than Chinese medicine.Cerebral infarction is that cerebral vessels is blocked suddenly, and the Therapeutic Principle alleviates cerebral edema, lowers blood viscosity, blood vessel dilating, anticoagulant and thrombolytic.Dialectical and the treatment of traditional Chinese medical science successive dynasties to cerebral infarction accumulated very rich experience and a large amount of effect sides medicine, and its etiology and pathogenesis has been formed the comparatively theory of system, still instructing the traditional Chinese medical science and the combination of Chinese and Western medicine to this sick clinical treatment so far effectively.Relevant in recent years this sick clinical research report is more, and also having developed some is the new Chinese medicine of indication with the apoplexy, but compares with the apoplexy sickness rate, mortality rate, the disability rate that raise day by day at present, and the new Chinese medicine of being developed still has the sense of deficiency.
The Chinese patent drugs for treatment of relevant cerebral thrombosis apoplexy apoplex involving the channels and collaterals.The general above-mentioned traditional ball powder preparation of respectively demonstrate,proving successive dynasties treatments " apoplexy " that adopts more.According to the retrieval, " national essential drugs Chinese medicine preparation kind catalogue " Chinese medicine preparation of recording cures mainly apoplexy person kind more than 30.Press syndrome-classification, windsyndrome caused by hyperactive liverYANG has An ' gong blood pressure-reducing ball, NAOLIQING WAN, clear dizzy paralysis treating medicine bolus, quick-acting cow-bezoar bolus; The obstruction of collateral caused by windphlegm card has ginseng restorative bolus, deep town wind ball, HUATUO ZAIZAO WAN, the urticaria of healing, fresh Succus Bambusae, Fufang Qianzheng cream, ginseng osmanthus restorative bolus: expectorant heat-blockage resistance card has cow-bezoar bolus for resurrection, niuhuang zhibao pills, office side's most valuable treasure ball, bolus of cow-bezoar for clearing heart-fire, Succus Bambusae phlegm-resolving pill, Calculus Bovis Awake, tablet of cow-bezoar for tranquilization, TONGGUAN FEN; Syndrome of static blood blocking collaterals has embolism extinguishing oral liquid, PIANTAN FUYUAN WAN, DAHUOLUO WAN, HUOLUO WAN, ZHONGFENG HUICHUN WAN, XIAOSHUAN ZAIZAO WAN, xingnao zaizao pill, NIAOXUEKANG KOUFUYE, thromboembolism preventing to protect flourish capsule, XIAOSHUAN TONGLUO PIAN, XUESAITONG ZHUSHEYE, anti-embolism regenerative pill, Moschus antithrombotic pill, NAOXUESHUAN PIAN.
Take a broad view of these kinds, clear and definite actually rare with the kind of the compound pattern of syndrome of apoplexy, and the dosage form of above-mentioned this type of medicine mostly is pill, the use inconvenience.
In recent years, very active to the study on prevention of similar disease, various medicines also appear on the market, about this type of medicine patent of invention is arranged also, but the medical material that most Chinese medicine preparation comprises is various, property of medicine complexity.For example, the Chinese patent application CN200510041960.3 of Zhao Hongwei, denomination of invention is " a kind of Chinese patent medicine of preventing and treating apoplexy ", and wherein said Chinese patent medicine is by giving birth to Radix Astragali Preparata, Radix Ginseng, Radix Pseudostellariae, Rhizoma Atractylodis Macrocephalae, Radix Angelicae Sinensis, Colla Corii Asini bead, baked polygonum capitatum, the burnt Cortex Eucommiae, Rhizoma Drynariae, Carapax Et Plastrum Testudinis (processed), Radix Ophiopogonis, Herba Taxilli, Rhizoma Gastrodiae, LUMBRICUS, the gold scorpion, Bombyx Batryticatus, Scolopendra, Concha Haliotidis, Rhizoma Chuanxiong, Radix Salviae Miltiorrhizae, Niu Xi, Semen Persicae, Flos Carthami, Olibanum (processed), Myrrha (processed), Su Tuyuan, Hirudo, Caulis Spatholobi, stir-baked SQUAMA MANITIS, Rhizoma Wenyujin Concisum, Zaocys, Fructus Chaenomelis Herba Siegesbeckiae, fry Ramulus Mori, Caulis Piperis Kadsurae, Radix Clematidis, Herba Lycopodii, Radix Saposhnikoviae, Rhizoma Et Radix Notopterygii, Ramulus Cinnamomi, the RHIZOMA TYPHONII PREPARATA sheet, Fructus Gleditsiae Abnormalis, Radix Puerariae, Spica Prunellae, Radix Et Rhizoma Rhei, Rhizoma Atractylodis (parched), Styrax, Pericarpium Citri Reticulatae, Radix Aucklandiae (Radix Vladimiriae), Lignum Dalbergiae Odoriferae, Radix Notoginseng, Borneolum Syntheticum, Ramulus Uncariae Cum Uncis, Rhizoma Acori Graminei, Radix Polygalae, Radix Scutellariae, Radix Paeoniae Rubra, Pollen Typhae, Fructus Amomi, Fructus Crataegi, Rhizoma Zingiberis, Poria and Radix Glycyrrhizae Preparata are mixed and made into medicament after pulverizing according to a certain ratio.
And for example, the Chinese patent application CN200410039479.6 of Wang Haijin, denomination of invention is " a kind of pharmaceutical composition for the treatment of apoplexy and preparation method thereof ", and the wherein said pharmaceutical composition that is used for the treatment of apoplexy mainly is made up of Radix Astragali Preparata, Radix Saposhnikoviae, Cortex Acanthopancis, Agkistrodon, Rhizoma Chuanxiong, Rhizoma Gastrodiae, Hirudo, Scolopendra, Radix Salviae Miltiorrhizae, Radix Achyranthis Bidentatae, Radix Clematidis, Rhizoma Acori Graminei, Herba Siegesbeckiae, Radix Glycyrrhizae Preparata crude drug.
The pharmaceutical composition that the present invention is used for the treatment of apoplexy and apoplexy sequela only comprises 3 kinds of Chinese crude drugs, and compares with existing similar medicine, and pharmaceutical composition of the present invention and various preparation have good curative effect to apoplexy and apoplexy sequela.
Summary of the invention
The object of the present invention is to provide a kind of pharmaceutical composition that is used for the treatment of apoplexy and/or apoplexy sequela, said composition Han You Herba Siegesbeckiae, Flos Carthami and river cattle lacquer, and optionally contain one or more pharmaceutical carriers.
Ratio of weight and number Shi Herba Siegesbeckiae 200-1000, the Flos Carthami 10-100 of various Chinese crude drug components and river cattle lacquer 10-100 in the pharmaceutical composition of the present invention.Preferably, the wherein ratio of weight and number of each component Wei Herba Siegesbeckiae 600, Flos Carthami 50 and river cattle lacquer 50.
Chong Herba Siegesbeckiae in the pharmaceutical composition of the present invention, its energy wind-damp dispelling, sharp joint have the removing blood stasis effect, are usually used in treating soreness of the waist and knees, quadriplegia and Fengshi Guanjie pain; Be aided with Flos Carthami Zhu Herba Siegesbeckiae promoting blood circulation to disperse blood clots and relieves pain; Be equipped with the cattle lacquer, removing blood stasis collateral dredging, easing joint movement.
Wherein employed Zhong Yao Cai Herba Siegesbeckiae, Latin is called Herba Siegesbeckia, for the rare Xian Siegesbeckia of feverfew orientalis L., gland obstruct the dry aerial parts of rare Xian Siegesbeckiapubescens Makino or the rare Xian Siegesbeckiaglabrescens of MAOGENG Makino.Herba Siegesbeckiae nature and flavor hardship, cold is returned the liver,spleen,kidney warp, has wind-damp dispelling, sharp joint and antidotal effect, and it is unable to can be used for rheumatic arthralgia muscles and bones, soreness of the waist and knees, quadriplegia, hemiplegia, rubella eczema etc.
Wherein employed Chinese crude drug river cattle lacquer, Latin is called Achyranthes officiualisKuan, the cattle pearlwort, Caryophyllaceae, about 40 kinds, be widely distributed in the whole world, China has 4 kinds, originates in the north and northeast, is common on the sebkha.Be used for the treatment of heat in the heart, qi stagnation blood stasis, have a pain in heart district, and heart beating is breathed hard and irritability etc.
Wherein employed Chinese crude drug Flos Carthami is the dried floral of feverfew Flos Carthami Carthamus tinctoriusL..The property suffering, temperature, GUIXIN, Liver Channel.The effect of promoting blood circulation to restore menstrual flow, stasis-dispelling and pain-killing is arranged, cure mainly dysmenorrhea amenorrhea, traumatic injury, joint aches, coronary heart disease.
Pharmaceutical composition of the present invention can be formulated to conventional pharmaceutical formulation, the preferred oral preparation, and for example tablet, capsule, granule, pill etc., for ease of taking and absorbing, preferred oral formulations is an oral liquid.
Pharmaceutical composition of the present invention and the various preparations that contain said composition can not add any pharmaceutical carrier, also can be as required, and optional one or more conventional pharmaceutical carriers of adding.Described carrier can be the conventional carrier of pharmaceutical field, for example liquid or solid excipient, diluent, wetting agent, antiseptic, sweeting agent, correctives and coloring agent etc.When the preparation oral formulations, the most frequently used pharmaceutical carrier for example is starch, dextrin, Pulvis Talci, sucrose, lactose, steviosin, water, yellow wine etc.
Can carry out according to the conventional principle of pharmaceutical field the kind of pharmaceutical carrier and/or the selection of consumption.Usually, the consumption of carrier can great changes have taken place, and for example, by weight, the consumption of pharmaceutical carrier can be about 1% to several times a amount of crude drug total amount.With regard to solid orally ingestible, the consumption of carrier can be about 10% to several times a amount of crude drug total amount, and for example the consumption of carrier is about 20% to 80% of a crude drug total amount; For example with regard to the oral liquid, the content of liquid excipient should be able to form solution or the suspension that is suitable for medicinal concentration at least with regard to liquid oral medicine; The content of other adjuvant such as sweeting agent, aromatic etc. should to be suitable for oral mouthfeel be principle so that oral liquid has; The use amount of antiseptic etc. should be a principle can guarantee the stability of this medicament in the operating period.
For example, when compositions of the present invention was formulated to oral liquid, wherein said pharmaceutical carrier was water, yellow wine and/or sweeting agent, and described water is pure water preferably; Wherein also preferred sweeting agent, for example steviosin, Sucralose etc., the preferably steviosin of using.
Another purpose of the present invention is to provide described preparation of drug combination method, and pharmaceutical composition of the present invention can prepare with the conventional method of this area.
For example, pharmaceutical composition of the present invention can prepare as follows:
(1) each component is decocted with water repeatedly;
(2) decoction liquor that merges is condensed into extractum;
(3) with after the extractum cooling, add required pharmaceutical carrier, obtain required pharmaceutical composition.
In this preparation method, before each component is decocted with water, also can at first with alcohol reflux repeatedly then the extracting solution that merges be condensed into extractum with each component.
That is, compositions of the present invention can prepare according to following method:
(1) with ethanol extraction repeatedly with each component;
(2) extracting solution that merges is condensed into extractum;
(3) medicinal residues behind step 1 ethanol extraction are decocted with water repeatedly;
(4) decoction liquor that merges is condensed into extractum;
(5) merge two kinds of cooled extractum, add required pharmaceutical carrier, obtain required pharmaceutical composition.
In the preparation method of aforementioned pharmaceutical compositions, the density of prepared the water extracted immersing paste in the time of 50 ℃ approximately is 1.10-1.12g/ml
3
Concrete, preparation of drug combination method of the present invention may further comprise the steps:
(1) with each component ethanol, preferred 75% alcohol reflux, and/or each component decocted with water repeatedly, the w/v of its Chinese crude drug and described ethanol or water is approximately 1: 2-8;
(2) alcohol extract or the decoction liquor that merges is condensed into extractum respectively;
(3) with after the extractum cooling, add required pharmaceutical carrier, promptly obtain required pharmaceutical composition.
More specifically, compositions of the present invention prepares according to following method:
(1) with each component with 75% alcohol reflux, its Chinese crude drug and alcoholic acid w/v are 1: 2-8;
(2) alcohol extract that merges is condensed into extractum;
(3) filtering residue with step 1 decocts with water repeatedly, and the w/v of its Chinese crude drug and water is 1: 2-8;
(4) decoction liquor that merges is condensed into extractum;
(5) merge cooled extractum, add required pharmaceutical carrier, promptly obtain required pharmaceutical composition.
All medical materials that the present invention uses can be by " concocting method described in the Chinese pharmacopoeia is concocted in advance.For example, wherein Suo Shi Yong De Herba Siegesbeckiae can adopt the stewing method to concoct in advance.
As required, the compositions that said method obtains can be made required preparation according to the conventional pharmaceutical methods of pharmaceutical field.After for example treating described extractum cooling, add liquid excipient such as water or yellow wine to predetermined volume, and optionally add other adjuvant such as sweeting agent, antiseptic, make the oral liquid in the pharmaceutical composition of the present invention; Or make required tablet, granule, capsule etc. according to the conventional pharmaceutical methods of other pharmaceutical field.
When prepared preparation is oral liquid in the above-mentioned composition preparation method, preferred said preparation used excipient be water or medicinal yellow wine, preferred water or medicinal yellow wine, more preferably medicinal yellow wine; Used sweeting agent is steviosin or Sucralose, preferred steviosin.
The pH value of using the oral liquid of method for preparing approximately is 4.3-7.0.
Another object of the present invention has provided the purposes that pharmaceutical composition of the present invention is used for the treatment of diseases such as apoplexy and/or apoplexy sequela, said composition has the effect of expelling wind and activating blood circulation, removing obstruction in the collateral to relieve pain, be used for the treatment of the apoplexy that obstruction of collaterals by blood stasis causes, and various apoplexy sequela, for example hemiplegia, numb limbs and tense tendons, dysphonia, facial hemiparalysis etc.
Another object of the present invention has provided the purposes that described pharmaceutical composition is used to prepare the medicine of diseases such as treatment apoplexy and/or apoplexy sequela, wherein described medicine can be the arbitrary suitable preparation in pharmaceutics field, for example described preparation can be oral formulations such as tablet, granule, capsule, solution etc., preferred oral liquid.
Prove that through pharmacological evaluation the present composition has tangible blood circulation promoting and blood stasis dispelling, anti-inflammatory analgesic and anti rheumatism action.Clinical practice is to apoplexy and various apoplexy sequela, and for example hemiplegia, numb limbs and tense tendons, dysphonia, facial hemiparalysis etc. have tangible curative effect.
Pharmaceutical composition of the present invention is when being used for above-mentioned treatment of diseases, and its consumption can be according to multiple factors vary, the time of for example concrete disease, the order of severity of disease, begin treatment, patient's body constitution, age and body weight etc.With the oral liquid is example, and the oral dose that calculates common per day for adults with the crude drug amount is about 10-50g, and preferably approximately 20-30g can once take, or take several times, for example divides secondary or takes for three times, to take better effects if several times.
The inventor has carried out clinical trial to pharmaceutical composition of the present invention, with the oral liquid of the embodiment of the invention 1 as trial drug, every day three times, each 10ml, duration of test is forbidden other activating blood and removing stasis drug.Test adopts the method for contrast to compare, and carries out statistical disposition with the T method of inspection.Result of the test shows that compositions of the present invention has the good curing effect to stroke patient.
Meanwhile, also the antiinflammatory action in the pharmaceutical composition of the present invention, hypotensive effect are tested, illustrate that arthroncus has the obvious suppression effect to the present composition to rat Ovum Gallus domesticus album; Blood pressure to anesthetized animal has tangible reduction effect.
About the toxicity in the pharmaceutical composition of the present invention, with the oral liquid plant trial drug of the embodiment of the invention 1, after measured, the LD when oral liquid of the present invention is used for intravenous injection
50Value is 45.54 ± 1.44g/kg; LD during oral administration
50Value is 257.6 ± 31.65g/kg, is 320 times of human therapy consumption, illustrates that compositions of the present invention is nontoxic substantially.
The pharmaceutical composition that the present invention is used for the treatment of apoplexy and apoplexy sequela only comprises 3 kinds of Chinese crude drugs, compares with existing similar medicine, and pharmaceutical composition of the present invention and various preparation thereof have good curative effect to apoplexy and apoplexy sequela.Because it is the preferred oral liquid formulations that uses, easy to use, to be easy to absorb also be a big advantage.
The specific embodiment
Below by concrete embodiment technical scheme of the present invention is further described, the embodiment that wherein exemplifies only is to explanation of the present invention, and can not limit protection scope of the present invention by any way.
The preparation of embodiment 1 oral liquid
1. take by weighing crude drug raw material: Herba Siegesbeckiae 600g, Flos Carthami 50g and river cattle lacquer 50g by following quantity;
2. each component is decocted with water secondary together, add water 4000-5000ml at every turn, each 30 minutes; Merge decoction liquor, filter, concentrate, obtain extractum 70-85g, paste-forming rate 10%-12%, the density of described extractum in the time of 50 ℃ is 1.10-1.12g/ml
3
3. natural cooling to wherein adding steviosin 3g, adds medicinal yellow wine 100ml, adds purified water and shakes up to 1000ml, and filtration is sub-packed in the bottle of 100 10ml.
The pH value of resulting oral liquid approximately is 5.0, and its crude drug content is that every 10ml contains 7g amount crude drug.
The preparation of embodiment 2 oral liquids
1. take by weighing crude drug raw material: Herba Siegesbeckiae 600g, Flos Carthami 50g and river cattle lacquer 50g by following quantity;
2. all medical materials add 75% ethanol 5000ml reflux, extract, 1 hour, filter, and concentrate and reclaim ethanol, obtain extractum 2-3g, paste-forming rate 3%-4%;
3. the medicinal residues that previous step is rapid decoct with water secondary, add water 4000-5000ml at every turn, and each 30 minutes, merge decoction liquor, the relative density when filtering and concentrating obtains 50 ℃ is 1.10-1.12g/ml
3Extractum 70-85g, paste-forming rate 10%-12%;
4. natural cooling, the extractum that obtains with step 2 merges, and to wherein adding steviosin 3g, adds pure water to 1000ml, shakes up, and filters, and is sub-packed in the bottle of 100 10ml.
Crude drug content in the resulting oral liquid is that every 10ml contains 7g amount crude drug.
The influence that embodiment 3 oral liquids of the present invention form the rat thrombus in vivo
Adopt thrombus in vivo to form instrument and measure the thrombus in vivo formation time.
Experiment purpose
Relatively two kinds of medicines provide scientific basis at the red collateral dredging oral liquid of the action intensity ， of prolong rats thrombus in vivo formation time Wei pig thrombolytic effect.
Experiment material
Experiment medicine: embodiment 1 apoplexy oral liquid 10ml/ props up, and defending Jing Pharmaceutical Co., Ltd by the Tonghua, Jilin Province provides, and lot number is 050408.The strong forever pharmaceutical Co. Ltd of contrast medicine, Dongbao of Tonghua produces, and lot number is 040901.Be mixed with desired concn with distilled water before the experiment, put 4 ℃ of refrigerators and preserve standby.Adopt variable concentrations equal-volume (20ml/kg) gastric infusion during experiment.
Control drug: NAOXUESHUAN KOUFUYE (the strong forever pharmaceutical factory of Dongbao of Tonghua product).
Animal: Wistar strain rat, body weight 200-250g, male and female half and half are provided by No. 2 Clinic Institute of the Medical University of China's Experimental Animal Center.The rat quality certification number: 2003-0013.
Instrument: the experimental thrombus in vivo of BT87-3 type forms analyzer, the development of medical college cardiovascular research chamber, packet header.
Method and result
Experiment is edited " herbal pharmacology experimental methodology " with reference to Li Yikui, front page, and Shanghai science tech publishing house, 1991, the described method of p145 is carried out.
Get 70 of Wistar rats, male and female half and half, five equilibrium is seven groups at random, every group 10, first group is the normal control group, give the distilled water of equal volume, second, three, four are respectively apoplexy oral liquid 6 of the present invention, 3,1.5ml/kg, the 5th, six, seven groups are respectively contrast medicine 6,3,1.5nl/kg, gastric infusion, once a day, continuous seven days, the administration volume is 20ml/kg, after the last administration 1 hour, uses chloral hydrate anesthesia, it is fixing to lie on the back, peel off a side common carotid artery, be about 1.5cm, avoid tissue temperature to influence the blood vessel wall temperature with near the tissue Polypropylence Sheet covering wound and adopt the experimental thrombus in vivo of BT87-3 type to form analyzer mensuration thrombus in vivo formation time.Experimental data adopts statistics " homogeneity of variance " and " seven checks " methods analyst to handle, relatively the significance of difference between each group.The results are shown in Table 1.
The influence of table 1 pair rat thrombus in vivo formation time (n=10, x ± s)
| Group | Dosage (ml/kg) | Thrombus in vivo formation time (min) |
| Normal control group embodiment 1 oral liquid embodiment 1 oral liquid embodiment 1 oral liquid NAOXUESHUAN KOUFUYE NAOXUESHUAN KOUFUYE NAOXUESHUAN KOUFUYE | ? 6 3 1.5 6 3 1.5 | 18.2±5.77 35.7±10.8*** 47.6±8.67*** 35.8±13.0** 33.6±10.9*** 35.5±13.9*** 34.2±19.0*** |
Annotate: compare * P＜0.05 with the normal control group; * P＜0.01; * * P＜0.001.
By table 1 result as seen, the oral liquid of the embodiment of the invention 1 is slightly longer than NAOXUESHUAN KOUFUYE rat thrombus in vivo formation time.But equal prolong rats thrombus in vivo formation time.
Conclusion
Experimental result shows, two kinds of equal obviously prolong rats thrombus in vivo formation times of medicine, and when same dose, embodiments of the invention 1 oral liquid thrombus formation time is slightly long, illustrates that this oral liquid has thrombolytic effect.
More than experiment shows with existing similar medicine and compares that compositions of the present invention has better therapeutic effect when being used for the treatment of apoplexy and/or apoplexy sequela.
Now described embodiment of the present invention in detail, clearly can do a lot of improvement and variation for a person skilled in the art and can not deviate from essence spirit of the present invention.All these changes and improvements think all within the scope of the present invention that its feature is determined by above-mentioned description.
Claims (20)
1. pharmaceutical composition that is used for the treatment of apoplexy, said composition is made by following raw medicaments in portion by weight: Herba Siegesbeckiae 200-1000, Flos Carthami 1-100 and river cattle lacquer 1-100.
2. according to the described pharmaceutical composition of claim 1, wherein said composition is made: Herba Siegesbeckiae 600, Flos Carthami 50 and river cattle lacquer 50 by following raw medicaments in portion by weight.
3. according to the described pharmaceutical composition of claim 2, the Herba Siegesbeckiae of De described in the Qi adopts the stewing method to concoct in advance.
4. according to any described pharmaceutical composition of claim 1-3, also contain one or more pharmaceutical carriers in the described compositions.
5. according to the described pharmaceutical composition of claim 4, wherein said compositions is an oral formulations.
6. according to the described pharmaceutical composition of claim 5, wherein said oral formulations is an oral liquid.
7. according to the described pharmaceutical composition of claim 6, the pharmaceutical carrier in the wherein said oral liquid is selected from water, medicinal yellow wine and/or sweeting agent.
8. according to the described pharmaceutical composition of claim 7, wherein said sweeting agent is a steviosin.
9. according to the described pharmaceutical composition of claim 6, the pH value of wherein said oral liquid is 4.3-7.0.
10. according to any described preparation of drug combination method of claim 1-3, this method may further comprise the steps:
(1) various crude drug is decocted with water repeatedly;
(2) decoction liquor that merges is condensed into extractum;
(3) with after the extractum cooling, obtain required pharmaceutical composition.
11. according to the described preparation of drug combination method of claim 10, the Herba Siegesbeckiae of De described in the Qi adopts the stewing method to concoct in advance.
12. according to the described preparation of drug combination method of claim 10, wherein the density of the resulting the water extracted immersing paste of step 2 in the time of 50 ℃ is 1.10-1.12g/ml
3
13., also contain one or more pharmaceutical carriers in the described compositions according to the described preparation of drug combination method of claim 10.
14., wherein before various crude drug are decocted with water, at first repeatedly, then the extracting solution that merges is condensed into extractum with alcohol reflux according to any described preparation of drug combination method of claim 10-13.
15. according to the described preparation of drug combination method of claim 14, wherein said ethanol is 75% ethanol.
16. according to the described preparation of drug combination method of claim 15, this method comprises:
(1) with various crude drug with 75% alcohol reflux, its Chinese crude drug and alcoholic acid w/v are 1: 2-8;
(2) alcohol extract that merges is condensed into extractum;
(3) filtering residue with step 1 decocts with water repeatedly, and the w/v of its Chinese crude drug and water is 1: 2-8;
(4) decoction liquor that merges is condensed into extractum;
(5) merge cooled extractum, add pharmaceutical carrier, promptly obtain required pharmaceutical composition.
17. according to the described preparation of drug combination method of claim 16, wherein the drug prepared compositions is an oral liquid.
18. according to the described preparation of drug combination method of claim 17, the pharmaceutical carrier in the wherein said oral liquid is selected from water, medicinal yellow wine and/or sweeting agent.
19. according to the described preparation of drug combination method of claim 17, the pH value of wherein said oral liquid is 4.3-7.0.
20. according to the application of any described pharmaceutical composition of claim 1-9 in the medicine of preparation treatment apoplexy and/or apoplexy sequela.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100830296A CN100420454C (en) | 2006-05-29 | 2006-05-29 | Pharmaceutical composition for treating apoplexy and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2006100830296A CN100420454C (en) | 2006-05-29 | 2006-05-29 | Pharmaceutical composition for treating apoplexy and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1883533A CN1883533A (en) | 2006-12-27 |
| CN100420454C true CN100420454C (en) | 2008-09-24 |
Family
ID=37581915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2006100830296A Active CN100420454C (en) | 2006-05-29 | 2006-05-29 | Pharmaceutical composition for treating apoplexy and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100420454C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102389450B (en) * | 2011-11-23 | 2014-04-16 | 通化卫京药业股份有限公司 | Xihong tongluo oral solution capable of quickly passing through blood-brain barrier |
| CN102631639A (en) * | 2012-04-23 | 2012-08-15 | 常州亚环环保科技有限公司 | Chinese medicament for treating cerebrovascular diseases and preparation method thereof |
| CN104435045B (en) * | 2014-12-25 | 2018-01-30 | 通化卫京药业股份有限公司 | A kind of Chinese medicine composition for treating apoplexy and its sequelae and preparation method thereof |
| CN106266759A (en) * | 2016-08-16 | 2017-01-04 | 甘肃鑫晟源生物科技开发有限责任公司 | A kind of granule for apoplexy sequela and rheumatic and rheumatoid diseases and preparation method thereof |
| CN108653364A (en) * | 2017-04-01 | 2018-10-16 | 通化卫京药业股份有限公司 | Application of the red dredging collateral oral solution of pig in preparing the drug for treating Post-stroke pain |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403119A (en) * | 2002-10-18 | 2003-03-19 | 吉林省长源药业有限公司 | Medicine for treating cerebral thrombus and its prepn |
-
2006
- 2006-05-29 CN CNB2006100830296A patent/CN100420454C/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1403119A (en) * | 2002-10-18 | 2003-03-19 | 吉林省长源药业有限公司 | Medicine for treating cerebral thrombus and its prepn |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1883533A (en) | 2006-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106421663A (en) | Medicine composition for treating rheumatoid bone disease and preparation method thereof | |
| CN100420454C (en) | Pharmaceutical composition for treating apoplexy and preparation method thereof | |
| CN103784890A (en) | Traditional Chinese medicine composition for treating bone diseases | |
| CN104740583A (en) | Traditional Chinese medicine preparation for relieving Crohn's disease and preparation method for traditional Chinese medicine preparation | |
| CN101015670A (en) | Preparation process of traditional Chinese medicine lotion for treating closed trauma | |
| CN104288496A (en) | Traditional Chinese medicine composition for treating constipation | |
| CN105943705A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis and preparation method thereof | |
| CN104337989A (en) | Traditional Chinese medicine composition containing centipeda minima and frankincense for treating gout | |
| CN105106634A (en) | Traditional Chinese medicine preparation for treating acute appendicitis and application thereof | |
| CN104740405B (en) | A kind of Chinese medicine preparation and preparation method for treating anaphylactoid purpura renal damage | |
| CN106237155A (en) | A kind of decoction medicine treating exogenous high fever and preparation method thereof | |
| CN104998158A (en) | Pharmaceutical composition for treating liver cirrhosis and application thereof | |
| CN104873659A (en) | Traditional Chinese medicament for treating eczema and preparation method thereof | |
| CN104840865A (en) | Traditional Chinese medicine preparation for treating gouty arthritis | |
| CN104127737A (en) | Pharmaceutical composition for preventing and treating postoperative complications of haemorrhoids and preparation method of pharmaceutical composition | |
| CN104547489A (en) | Use of traditional Chinese medicine composition in preparation of medicine for treating comminuted fracture | |
| CN116570696B (en) | Traditional Chinese medicine composition for treating prostatitis and preparation method and application thereof | |
| CN110279823B (en) | Traditional Chinese medicine composition for treating dengue fever and preparation method thereof | |
| CN108567926B (en) | Traditional Chinese medicine composition for treating blood stasis collateral blocking type autoimmune hepatitis and preparation method thereof | |
| CN106266576A (en) | A kind of can the pill medicine effectively treating apoplexy and preparation method thereof | |
| CN105770617A (en) | Application of medicine composition in preparation of medicine for treating hemorrhoids | |
| CN105943700A (en) | Traditional Chinese medicine composition capable of tonifying kidney and relieving paralysis and preparation method and application thereof | |
| CN105169277A (en) | Fructus gardeniae oral liquid capable of protecting liver and benefiting gallbladder and preparation method thereof | |
| CN104288282A (en) | Traditional Chinese medicinal composition for treating rheumatic arthritis and preparation method thereof | |
| CN104689254A (en) | Traditional Chinese medicine composition for treating psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: TONGHUA WEI JING PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: TONGHUA WEIJING PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Tonghua City, Jilin Province Dongchang District Long Street No. 16 Patentee after: Tonghua Weijing Pharmaceutical Co., Ltd. Address before: Tonghua City, Jilin Province Dongchang District Long Street No. 16 Patentee before: Tonghua Weijing Pharmaceutical Co., Ltd. |